Parallel Advisors’s Kezar Life Sciences KZR Stock Holding History

Parallel Advisors’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6	Closed	-$191	–	3456
2023 Q1	$191	Buy	+6	New	+$347	﹤0.01%	3283

Other funds holding KZR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Parallel Advisors's KZR Position: Q2 2023 in Review

Parallel Advisors sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 6 shares — an estimated $191 sold.

Parallel Advisors first reported a position in KZR in Q1 2023 and held it in 1 quarter. The position peaked at $191 in Q1 2023. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

Parallel Advisors reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
Parallel Advisors sold 6 Kezar Life Sciences shares in Q2 2023, an estimated $191.
Parallel Advisors first reported a position in Kezar Life Sciences in Q1 2023 and held it in 1 quarter.
Parallel Advisors's Kezar Life Sciences position peaked at $191 in Q1 2023.
104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Parallel Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.